Newborn Screening Expansion: SMA Success Raises Questions on DMD 2026

The decision to introduce newborn screening for spinal muscular atrophy (SMA) is a major breakthrough for families and campaigners, as all newborns in England will be screened for SMA from 2027. Early diagnosis means children can access treatment sooner, improving outcomes and giving families clarity at a crucial time. However, this success raises an important question: why are other serious genetic conditions, such as Duchenne muscular dystrophy (DMD), still excluded from newborn screening programmes?

Why SMA Screening Matters

Spinal muscular atrophy is a severe genetic disorder that affects motor neurons, leading to muscle weakness and early death if untreated. With the inclusion of SMA in the newborn screening program, families can now receive immediate diagnosis and access life-changing therapies like Spinraza and Zolgensma. This early intervention dramatically improves quality of life and survival rates.

The Case for Duchenne Muscular Dystrophy Screening

About 100 boys are born with DMD each year. It causes progressive muscle weakness and is often diagnosed only after years of uncertainty. Although new treatments such as Givinostat are beginning to offer hope for some young people, early diagnosis remains vital. It can help families access information, specialist care and support much sooner, and may allow more children to benefit from emerging treatments.

Impact on Families

Through research with families affected by DMD and organisations such as Duchenne UK, I have heard repeated accounts of delayed diagnoses, multiple GP visits and years spent searching for answers. Some parents only discover the condition after having additional children who are also affected. For many, the diagnosis comes after a long and exhausting journey.

Key Takeaways

• Newborn screening for SMA is a major step forward, but DMD remains excluded.
• Early diagnosis for DMD could allow families to access specialist care and emerging treatments sooner.
• Campaigners continue to push for broader newborn screening programs for all rare genetic conditions.
• Family support and planning are significantly improved with early detection.

Barriers to Broader Screening

Newborn screening is not only about access to treatment. It also enables families to plan for the future and secure the support their children need. Too often, families of disabled children face lengthy battles with services before receiving appropriate help. Campaigners deserve enormous credit for achieving newborn screening for SMA. I hope this milestone marks the beginning of a broader conversation about other rare genetic conditions and the barriers families continue to face.

FAQ

Every child deserves the best possible start in life, and every family deserves timely diagnosis, meaningful support and the opportunity to thrive. Dr Janet Hoskin, associate professor at the University of East London, underscores the urgent need for expanded newborn screening to include conditions like DMD. The conversation must continue until all children benefit from early detection.